David J Heal Selected Research

David J Heal Research Topics

Disease

12	Attention Deficit Disorder with Hyperactivity (Attention Deficit Hyperactivity Disorder) 01/2024 - 01/2006
5	Obesity 01/2022 - 03/2004
4	Binge-Eating Disorder (Binge Eating Disorder) 01/2024 - 01/2016
4	Substance-Related Disorders (Drug Abuse) 01/2023 - 01/2019
4	Bulimia (Binge Eating) 01/2017 - 12/2015
3	Mental Disorders (Mental Disorder) 01/2024 - 11/2018
3	Schizophrenia (Dementia Praecox) 01/2022 - 01/2012
2	Parkinson Disease (Parkinson's Disease) 01/2019 - 09/2012
2	Glucose Intolerance 03/2012 - 01/2012
1	Nervous System Diseases (Neurological Disorders) 11/2022
1	Weight Loss (Weight Reduction) 01/2022
1	Heroin Dependence (Heroin Abuse) 10/2021
1	Restless Legs Syndrome (Restless Legs) 09/2012
1	Cocaine-Related Disorders (Cocaine Addiction) 09/2012
1	Body Weight (Weight, Body) 03/2012
1	Weight Gain 01/2012
1	Insulin Resistance 01/2012
1	Type 2 Diabetes Mellitus (MODY) 01/2012
1	Diabetic Ketoacidosis (Ketoacidosis, Diabetic) 01/2012
1	Metabolic Syndrome (Dysmetabolic Syndrome X) 12/2009
1	Tics (Tic) 01/2006
1	Neurodegenerative Diseases (Neurodegenerative Disease) 01/2005
1	Alzheimer Disease (Alzheimer's Disease) 01/2005
1	Tachycardia (Tachyarrhythmias) 03/2004

Drug/Important Bio-Agent (IBA)

8	Lisdexamfetamine Dimesylate FDA Link 01/2024 - 06/2013
7	ProdrugsIBA 01/2024 - 06/2013
5	Methylphenidate (Ritalin)FDA LinkGeneric 01/2024 - 01/2006
4	Dextroamphetamine (Dexedrine)FDA LinkGeneric 01/2024 - 06/2013
3	Adrenergic Receptors (Adrenergic Receptor)IBA 07/2023 - 03/2004
3	Hallucinogens (Psychedelics)IBA 01/2023 - 11/2018
3	Norepinephrine (Noradrenaline)FDA LinkGeneric 01/2022 - 03/2004
3	Amphetamine (Amfetamine)FDA LinkGeneric 10/2013 - 01/2012
2	Controlled SubstancesIBA 01/2023 - 11/2022
2	Serotonin (5 Hydroxytryptamine)IBA 01/2022 - 03/2004
2	Neurotransmitter Agents (Neurotransmitter)IBA 01/2019 - 01/2017
2	Dopamine (Intropin)FDA LinkGeneric 01/2017 - 01/2012
2	Neurokinin-1 Receptors (Neurokinin 1 Receptor)IBA 12/2014 - 10/2014
1	4- (3,4- dichlorophenyl)- 1,2,3,4- tetrahydronaphthalen- 1- amineIBA 01/2022
1	SEP-363856IBA 01/2022
1	Trace amine-associated receptor 1IBA 01/2022
1	Pemetrexed (MTA)FDA Link 01/2022
1	Serotonin 5-HT1 Receptor AgonistsIBA 01/2022
1	methyllycaconitineIBA 10/2021
1	Heroin (Diamorphine)IBA 10/2021
1	Nicotinic Receptors (Nicotinic Acetylcholine Receptor)IBA 10/2021
1	Antihypertensive Agents (Antihypertensives)IBA 01/2019
1	Dihydroxyphenylalanine (Dopa)IBA 01/2019
1	6-chloro-2-(1-piperazinyl)pyrazine (CPP)IBA 01/2019
1	Narcotic Antagonists (Opioid Antagonists)IBA 01/2017
1	S(8)IBA 01/2017
1	nalmefene (Revex)FDA Link 01/2017
1	Opioid Receptors (Opioid Receptor)IBA 01/2017
1	Biomarkers (Surrogate Marker)IBA 01/2016
1	Complement System Proteins (Complement)IBA 01/2016
1	Atomoxetine Hydrochloride (Strattera)FDA LinkGeneric 12/2014
1	Guanfacine (Tenex)FDA LinkGeneric 10/2014
1	Substance PIBA 10/2014
1	Lysine (L-Lysine)FDA Link 10/2013
1	Modafinil (Provigil)FDA Link 10/2013
1	ropinirole (Requip)FDA LinkGeneric 09/2012
1	SugarsIBA 07/2012
1	ibipinabantIBA 03/2012
1	RimonabantIBA 03/2012
1	Antipsychotic Agents (Antipsychotics)IBA 01/2012
1	Anti-Obesity Agents (Antiobesity Drugs)IBA 12/2009
1	Sympathomimetics (Sympathomimetic Amines)IBA 01/2006
1	NeurotoxinsIBA 01/2005
1	Amyloid beta-PeptidesIBA 01/2005
1	amyloid beta-protein (1-42)IBA 01/2005
1	SodiumIBA 01/2005
1	sibutramine (Meridia)FDA Link 03/2004

Therapy/Procedure

5	Drug Therapy (Chemotherapy) 01/2022 - 12/2009
5	Therapeutics 01/2022 - 01/2005
1	Combined Modality Therapy 01/2022
1	Self Administration (Administration, Self) 10/2021
1	Glycemic Control 01/2012